The Conversation (0)
British drug maker GlaxoSmithKline (LSE:GSK) hopes to get the green light for a prototype vaccine against malaria after trials showed it offered children a partial shield against the disease, South China Morning Post reported.
British drug maker GlaxoSmithKline (LSE:GSK) hopes to get the green light for a prototype vaccine against malaria after trials showed it offered children a partial shield against the disease, South China Morning Post reported.
As quoted in the market news:
Results for the Phase III stage of the closely-followed RTS,S vaccine were unveiled at a conference in Durban, South Africa, gathering experts on malaria in Africa.
It showed that 18 months after vaccination, children aged five to 17 months had a 46-per cent reduction in the risk of clinical malaria compared to unvaccinated peers.
But in infants aged six to 12 weeks at the time of vaccination, efficacy was lower: a 27-per cent reduction in risk.